Skip to content
MARKETS / NASDAQ / PGEN
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Precigen, Inc. PGEN

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$9.7M
▲ 146.7% YoY
$-250.6M
$-89.8M
In brief

What this company does

We are leveraging our proprietary technology platforms to develop product candidates designed to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. In August 2025, the FDA granted full approval to our product, Papzimeos (zopapogene imadenovec-drba, PRGN-2012), for the treatment of adults with recurrent respiratory papillomatosis (RRP). We have developed a proprietary electroporation device, UltraPorator, designed to further streamline and ensure the rapid and cost-effective manufacturing of UltraCAR-T therapies. We have completed enrollment in the Phase 1b clinical trial of PRGN-3006.

Written from the business description in Precigen, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 25 March 2026. Every sentence was checked against that document before publication.

Growth
USD 9.7M
Revenue, FY2025 · full 15-year series below
Revenue $M Net income $M
FY2025 · Revenue 9.7 · Net income -250.6
80M160M-200M-400M20112013201520172019202120232025
Compound annual growth
−28.9%
−21.3%
−25.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −21.3% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−2588 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -1141.1% · Net -2588.2%
-1000%-2000%-3000%20112013201520172019202120232025
ROE
FY2025 · ROE -843.6%
-500%20112013201520172019202120232025

Each USD of equity lost 844 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -89.8
8M16M-80M-160M20112013201520172019202120232025

Total assetsUSD 155.5M
EquityUSD 20.9M
CashUSD 30.2M
Gross debtUSD 93.2M
Net debtUSD 62.9M
Current ratio3.09×

Net debt stands at 301% of equity.

The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017201620152014201320122011
Revenue $B0.00.00.00.00.00.00.10.20.20.20.20.10.00.00.0
Operating income $B−0.1−0.1−0.1−0.1−0.1−0.1−0.2−0.4−0.1−0.1−0.1−0.1−0.1−0.1−0.1
EBITDA $B−0.1−0.1−0.1−0.1−0.1−0.1−0.1−0.4−0.0−0.1−0.1−0.1−0.1−0.1−0.1
Income tax $B0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.00.0−0.00.00.00.0
Net income $B−0.3−0.1−0.10.0−0.1−0.2−0.3−0.5−0.1−0.2−0.1−0.1−0.0−0.1−0.1
Free cash flow $B−0.1−0.1−0.1−0.1−0.1−0.1−0.2−0.2−0.2−0.10.0−0.0−0.1−0.1−0.1
EPS, diluted $−1.37−0.47−0.390.14−0.47−1.02−2.09−3.93−0.98−1.58−0.76−0.83−1.40−18.77−18.92
Dividend / sh $···············
Payout %···············
ROE %−843.6−160.8−78.424.2−105.6−245.6−148.3−113.6−21.4−29.8−15.7−21.8−172.6··
Shares out B0.350.290.250.210.210.190.160.160.120.120.120.100.100.01·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 58 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 31 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inVirginia
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2011

Share this section

Download image